发布: 2018年05月05日第8卷第9期 DOI: 10.21769/BioProtoc.2831 浏览次数: 5910
评审: Yannick DebingKristin ShinglerBalaji Olety Amaranath
相关实验方案
从小鼠结肠组织中分离 RNA 并采用qRT -PCR 检测炎症细胞因子
Ibrahim M. Sayed [...] Laura Crotty Alexander
2023年03月20日 2495 阅读
用细胞增殖和基因表达测定法从柏氏血矛线虫排泄物和分泌物中筛选具有免疫潜力的分子
Jocelyn Maza-Lopez [...] Carla O. Contreras-Ochoa
2023年06月20日 708 阅读
Abstract
Human norovirus is the most common cause of acute gastroenteritis worldwide, resulting in estimated mortality of ~210,000 each year, of whom most are children under the age of five. However, norovirus can infect people of all age groups. There is a risk of prolonged infection in children, the elderly and patients who are immunocompromised. To study the inhibition of persistent norovirus replication by small molecule antivirals in vivo, we used a murine norovirus CR6 strain (MNV.CR6). We demonstrated earlier that efficient small molecules can reduce viral shedding in the stool of infected mice. Here we present how to generate the MNV.CR6 virus stock, infect type I and II interferon receptor knockout AG129 mice via oral gavage, administer antivirals to mice, and quantify viral genome copies in the stool of these mice.
Keywords: Murine norovirus (鼠诺如病毒)Background
Human noroviruses are an important cause of gastroenteritis. Although most norovirus infections are acute and self-limiting, the infection can become chronic in patients with an immunodeficient status, particularly in solid organ and hematopoietic stem cell transplant recipients, patients undergoing chemotherapy and patients with AIDS (Westhoff et al., 2009; Green, 2014; Angarone et al., 2016). Prolonged norovirus infection is also observed in young children and the elderly resulting in an increased duration of illness, increased defecations and virus shedding for up to 47 days (Murata et al., 2007; Aoki et al., 2010). Reduction of immunosuppressive therapy is, when feasible, the strategy of choice to control the infection in transplant recipients. Specific antiviral therapies to treat (chronic) norovirus gastroenteritis are not available. To assess the inhibitory effect of small molecules on persistent norovirus infections, we used a mouse-adapted persistent murine norovirus (MNV.CR6) in type I and II interferon receptor knockout AG129 mice (Strong et al., 2012). MNV is a genogroup V norovirus that is widely used as a surrogate for human noroviruses, which comprises around 30 strains (Karst et al., 2003; Wobus et al., 2004). The MNV.CR6 is avirulent in AG129 and STAT1-/- mice, but replicates for weeks to months in wild type mice and to higher titers in innate immune-deficient mice (Thackray et al., 2007). The MNV.CR6 strain has a tropism for the proximal colon and the cecum, where it persists and replicates more efficiently than the MNV.CW3 strain, which causes acute infection (Arias et al., 2012; Nice et al., 2013).
Materials and Reagents
Equipment
Software
Procedure
文章信息
版权信息
© 2018 The Authors; exclusive licensee Bio-protocol LLC.
如何引用
Dycke, J. V., Neyts, J. and Rocha-Pereira, J. (2018). Assessing the Efficacy of Small Molecule Inhibitors in a Mouse Model of Persistent Norovirus Infection. Bio-protocol 8(9): e2831. DOI: 10.21769/BioProtoc.2831.
分类
微生物学 > 体内实验模型 > 病毒
分子生物学 > RNA > qRT-PCR
您对这篇实验方法有问题吗?
在此处发布您的问题,我们将邀请本文作者来回答。同时,我们会将您的问题发布到Bio-protocol Exchange,以便寻求社区成员的帮助。
提问指南
+ 问题描述
写下详细的问题描述,包括所有有助于他人回答您问题的信息(例如实验过程、条件和相关图像等)。
Share
Bluesky
X
Copy link